Impax yanks 300mg generic Wellbutrin after failing equivalence test
This article was originally published in Scrip
Impax has withdrawn from the US market its generic form of extended-release bupropion hydrochloride, which was being marketed by its partner Teva as Budeprion XL 300, after regulators said the medicine failed to demonstrate therapeutic equivalence to the same dosage strength as GlaxoSmithKline's innovator product Wellbutrin XL 300mg, an antidepressant approved to treat major depressive disorder and to prevent seasonal affective disorder.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.